206 related articles for article (PubMed ID: 36602046)
1. Real-world effectiveness of sotrovimab and remdesivir for early treatment of high-risk hospitalized COVID-19 patients: A propensity score adjusted retrospective cohort study.
Koh LP; Chua SL; Vasoo S; Toh MPHS; Cutter JN; Nah PH; Leo YS; Tay JX; Young BE; Lye DC; Ong SWX
J Med Virol; 2023 Feb; 95(2):e28460. PubMed ID: 36602046
[TBL] [Abstract][Full Text] [Related]
2. Real-world effectiveness of early remdesivir and sotrovimab in the highest-risk COVID-19 outpatients during the Omicron surge.
Piccicacco N; Zeitler K; Ing A; Montero J; Faughn J; Silbert S; Kim K
J Antimicrob Chemother; 2022 Sep; 77(10):2693-2700. PubMed ID: 35913836
[TBL] [Abstract][Full Text] [Related]
3. Changing patterns and clinical outcomes of hospitalized patients with COVID-19 severe pneumonia treated with remdesivir according to vaccination status: results from a real-world retrospective study.
Mengato D; Mazzitelli M; Francavilla A; Bettio M; Sasset L; Presa N; Pivato L; Lo Menzo S; Trevenzoli M; Venturini F; Gregori D; Cattelan AM
Clin Exp Med; 2023 Oct; 23(6):2749-2756. PubMed ID: 36961678
[TBL] [Abstract][Full Text] [Related]
4. Real-World Use of Sotrovimab for Pre-Emptive Treatment in High-Risk Hospitalized COVID-19 Patients: An Observational Cross-Sectional Study.
Ong SWX; Ren D; Lee PH; Sutjipto S; Dugan C; Khoo BY; Tay JX; Vasoo S; Young BE; Lye DC
Antibiotics (Basel); 2022 Mar; 11(3):. PubMed ID: 35326808
[TBL] [Abstract][Full Text] [Related]
5. Sotrovimab in Hospitalized Patients with SARS-CoV-2 Omicron Variant Infection: a Propensity Score-Matched Retrospective Cohort Study.
Woo MS; Brehm TT; Fischer M; Heyer A; Wichmann D; Jordan S; Nörz D; Lütgehetmann M; Addo MM; Lohse AW; Schmiedel S; Kluge S; Schulze Zur Wiesch J
Microbiol Spectr; 2023 Feb; 11(1):e0410322. PubMed ID: 36475890
[No Abstract] [Full Text] [Related]
6. Comparable outcomes of outpatient remdesivir and sotrovimab among high-risk patients with mild to moderate COVID-19 during the omicron BA.1 surge.
Chesdachai S; Rivera CG; Cole KC; Teaford HR; Gonzalez Suarez ML; Larsen JJ; Ganesh R; Tulledge-Scheitel S; Razonable RR
Sci Rep; 2024 Mar; 14(1):5430. PubMed ID: 38443438
[TBL] [Abstract][Full Text] [Related]
7. Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
Gupta A; Gonzalez-Rojas Y; Juarez E; Crespo Casal M; Moya J; Rodrigues Falci D; Sarkis E; Solis J; Zheng H; Scott N; Cathcart AL; Parra S; Sager JE; Austin D; Peppercorn A; Alexander E; Yeh WW; Brinson C; Aldinger M; Shapiro AE;
JAMA; 2022 Apr; 327(13):1236-1246. PubMed ID: 35285853
[TBL] [Abstract][Full Text] [Related]
8. Remdesivir in combination with dexamethasone for patients hospitalized with COVID-19: A retrospective multicenter study.
Gressens SB; Esnault V; De Castro N; Sellier P; Sene D; Chantelot L; Hervier B; Delaugerre C; Chevret S; Molina JM;
PLoS One; 2022; 17(2):e0262564. PubMed ID: 35176057
[TBL] [Abstract][Full Text] [Related]
9. Experience of the United Arab Emirates in the use of monoclonal antibody drug sotrovimab in high-risk vaccinated and unvaccinated patients with COVID-19: an observational cohort study.
Abdalateef S; Al Meheiri NM; Nassef M; Shorrab AA; Hashimi OAR; Allam S; Alnaqbi MS; Al-Rifai RH
BMJ Open; 2023 Jan; 13(1):e066095. PubMed ID: 36627160
[TBL] [Abstract][Full Text] [Related]
10. Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19 During SARS-CoV-2 Delta and Omicron Waves in the USA.
Cheng MM; Reyes C; Satram S; Birch H; Gibbons DC; Drysdale M; Bell CF; Suyundikov A; Ding X; Maher MC; Yeh W; Telenti A; Corey L
Infect Dis Ther; 2023 Feb; 12(2):607-621. PubMed ID: 36629998
[TBL] [Abstract][Full Text] [Related]
11. Real-life experience with remdesivir for treatment of COVID-19 among older adults: a multicentre retrospective study.
Margalit I; Tiseo G; Ripa M; Borghi V; Green H; Prendki V; Riccardi N; Perego GB; Grembiale A; Galli L; Tinelli M; Castagna A; Mussini C; Falcone M; Yahav D
J Antimicrob Chemother; 2023 Jun; 78(6):1505-1509. PubMed ID: 37086215
[TBL] [Abstract][Full Text] [Related]
12. Association of Remdesivir Treatment With Survival and Length of Hospital Stay Among US Veterans Hospitalized With COVID-19.
Ohl ME; Miller DR; Lund BC; Kobayashi T; Richardson Miell K; Beck BF; Alexander B; Crothers K; Vaughan Sarrazin MS
JAMA Netw Open; 2021 Jul; 4(7):e2114741. PubMed ID: 34264329
[TBL] [Abstract][Full Text] [Related]
13. Patients with moderate to severe COVID-19 outcomes on remdesivir according to baseline 4C mortality score.
Sellers J; Chang J; Jones J; Hintze TD
Pulm Pharmacol Ther; 2023 Feb; 78():102188. PubMed ID: 36603741
[TBL] [Abstract][Full Text] [Related]
14. Real world effectiveness of sotrovimab in preventing COVID-19-related hospitalisation or death in patients infected with Omicron BA.2.
Behzad A; Mohamed A; Ali A; Niinuma S; Butler AE; Alqahtani M
J Infect Public Health; 2024 Feb; 17(2):315-320. PubMed ID: 38160562
[TBL] [Abstract][Full Text] [Related]
15. Comparative effectiveness of sotrovimab and molnupiravir for prevention of severe covid-19 outcomes in patients in the community: observational cohort study with the OpenSAFELY platform.
Zheng B; Green ACA; Tazare J; Curtis HJ; Fisher L; Nab L; Schultze A; Mahalingasivam V; Parker EPK; Hulme WJ; Bacon SCJ; DeVito NJ; Bates C; Evans D; Inglesby P; Drysdale H; Davy S; Cockburn J; Morton CE; Hickman G; Ward T; Smith RM; Parry J; Hester F; Harper S; Mehrkar A; Eggo RM; Walker AJ; Evans SJW; Douglas IJ; MacKenna B; Goldacre B; Tomlinson LA
BMJ; 2022 Nov; 379():e071932. PubMed ID: 36384890
[TBL] [Abstract][Full Text] [Related]
16. What Is the Efficacy of Sotrovimab in Reducing Disease Progression and Death in People with COVID-19 during the Omicron Era? Answers from a Real-Life Study.
De Vito A; Colpani A; Poliseno M; Diella L; Ieva FRP; Belati A; Papale R; Babudieri S; De Santis L; Saracino A; Lo Caputo S; Madeddu G
Viruses; 2023 Aug; 15(8):. PubMed ID: 37632099
[TBL] [Abstract][Full Text] [Related]
17. Clinical Improvement, Outcomes, Antiviral Activity, and Costs Associated With Early Treatment With Remdesivir for Patients With Coronavirus Disease 2019 (COVID-19).
Wong CKH; Lau KTK; Au ICH; Xiong X; Lau EHY; Cowling BJ
Clin Infect Dis; 2022 Apr; 74(8):1450-1458. PubMed ID: 34265054
[TBL] [Abstract][Full Text] [Related]
18. Remdesivir for the Treatment of Severe COVID-19: A Community Hospital's Experience.
Lee S; Santarelli A; Caine K; Schritter S; Dietrich T; Ashurst J
J Am Osteopath Assoc; 2020 Dec; 120(12):926-933. PubMed ID: 33136164
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19.
Garibaldi BT; Wang K; Robinson ML; Zeger SL; Bandeen-Roche K; Wang MC; Alexander GC; Gupta A; Bollinger R; Xu Y
JAMA Netw Open; 2021 Mar; 4(3):e213071. PubMed ID: 33760094
[TBL] [Abstract][Full Text] [Related]
20. Early Use of Remdesivir and Risk of Disease Progression in Hospitalized Patients With Mild to Moderate COVID-19.
Falcone M; Suardi LR; Tiseo G; Barbieri C; Giusti L; Galfo V; Forniti A; Caroselli C; Della Sala L; Tempini S; Okoye C; Monzani F; Menichetti F
Clin Ther; 2022 Mar; 44(3):364-373. PubMed ID: 35120742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
